<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39391007</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-8927</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cell insight</Title><ISOAbbreviation>Cell Insight</ISOAbbreviation></Journal><ArticleTitle>Modeling respiratory tract diseases for clinical translation employing conditionally reprogrammed cells.</ArticleTitle><Pagination><StartPage>100201</StartPage><MedlinePgn>100201</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100201</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cellin.2024.100201</ELocationID><Abstract><AbstractText>Preclinical models serve as indispensable tools in translational medicine. Specifically, patient-derived models such as patient-derived xenografts (PDX), induced pluripotent stem cells (iPSC), organoids, and recently developed technique of conditional reprogramming (CR) have been employed to reflect the host characteristics of diseases. CR technology involves co-culturing epithelial cells with irradiated Swiss-3T3-J2 mouse fibroblasts (feeder cells) in the presence of a Rho kinase (ROCK) inhibitor, Y-27632. CR technique facilitates the rapid conversion of both normal and malignant cells into a "reprogrammed stem-like" state, marked by robust in vitro proliferation. This is achieved without reliance on exogenous gene expression or viral transfection, while maintaining the genetic profile of the parental cells. So far, CR technology has been used to study biology of diseases, targeted therapies (precision medicine), regenerative medicine, and noninvasive diagnosis and surveillance. Respiratory diseases, ranking as the third leading cause of global mortality, pose a significant burden to healthcare systems worldwide. Given the substantial mortality and morbidity rates of respiratory diseases, efficient and rapid preclinical models are imperative to accurately recapitulate the diverse spectrum of respiratory conditions. In this article, we discuss the applications and future potential of CR technology in modeling various respiratory tract diseases, including lung cancer, respiratory viral infections (such as influenza and Covid-19 and etc.), asthma, cystic fibrosis, respiratory papillomatosis, and upper aerodigestive track tumors. Furthermore, we discuss the potential utility of CR in personalized medicine, regenerative medicine, and clinical translation.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daneshdoust</LastName><ForeName>Danyal</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qi-En</ForeName><Initials>QE</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Wexner Medical Center, Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xuefeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Pathology, Urology, and Radiation Oncology, Wexner Medical Center, Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Cell Insight</MedlineTA><NlmUniqueID>9918557775706676</NlmUniqueID><ISSNLinking>2772-8927</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">Conditional reprogramming</Keyword><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Cystic fibrosis</Keyword><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">Preclinical models</Keyword><Keyword MajorTopicYN="N">Respiratory diseases</Keyword><Keyword MajorTopicYN="N">Respiratory papillomatosis</Keyword><Keyword MajorTopicYN="N">Respiratory viral infections</Keyword><Keyword MajorTopicYN="N">Translational medicine</Keyword></KeywordList><CoiStatement>Several patents for CR technology have been awarded to Georgetown University by the US Patent Office. The license for this technology has been given to a Maryland-based start-up company for commercialization. The inventor, X.L., and Georgetown University receive potential royalties and payments from the company. CR media and CR cells have been distributed by Propagenix (acquired by StemCell Technologies), Fisher Scientific, ATCC, etc. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39391007</ArticleId><ArticleId IdType="pmc">PMC11462205</ArticleId><ArticleId IdType="doi">10.1016/j.cellin.2024.100201</ArticleId><ArticleId IdType="pii">S2772-8927(24)00056-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alamri A.M., et al. Primary cancer cell culture: Mammary-optimized vs conditional reprogramming. Endocrine-Related Cancer. 2016;23(7):535–554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962879</ArticleId><ArticleId IdType="pubmed">27267121</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamri A.M., et al. Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing. Disease models &amp; mechanisms. 2018;11(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818080</ArticleId><ArticleId IdType="pubmed">29419396</ArticleId></ArticleIdList></Reference><Reference><Citation>Awatade N.T., et al. Significant functional differences in differentiated Conditionally Reprogrammed (CRC)-and Feeder-free Dual SMAD inhibited-expanded human nasal epithelial cells. Journal of Cystic Fibrosis. 2021;20(2):364–371.</Citation><ArticleIdList><ArticleId IdType="pubmed">33414087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bear C.E. A therapy for most with cystic fibrosis. Cell. 2020;180(2):211.</Citation><ArticleIdList><ArticleId IdType="pubmed">31978337</ArticleId></ArticleIdList></Reference><Reference><Citation>Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer. 2004;4(9):707–717.</Citation><ArticleIdList><ArticleId IdType="pubmed">15343277</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S.P., et al. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2023;208(10):1026–1041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10867924</ArticleId><ArticleId IdType="pubmed">37560988</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazek E., Borgia J. Simulated stereotactic Body radiation therapy (SBRT) of patient-derived non-small cell lung cancer (NSCLC) cultured by conditional reprogramming: Radiobiological comparison with established cell lines. International Journal of Radiation Oncology, Biology, Physics. 2020;108(3):e519.</Citation></Reference><Reference><Citation>Borodovsky A., et al. Generation of stable PDX derived cell lines using conditional reprogramming. Molecular Cancer. 2017;16(1):177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719579</ArticleId><ArticleId IdType="pubmed">29212548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukowy-Bieryłło Z. Long-term differentiating primary human airway epithelial cell cultures: How far are we? Cell Communication and Signaling. 2021;19(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159066</ArticleId><ArticleId IdType="pubmed">34044844</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler C.R., et al. Rapid expansion of human epithelial stem cells suitable for airway tissue engineering. American Journal of Respiratory and Critical Care Medicine. 2016;194(2):156–168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003214</ArticleId><ArticleId IdType="pubmed">26840431</ArticleId></ArticleIdList></Reference><Reference><Citation>Callinan P.A., Feinberg A.P. The emerging science of epigenomics. Human Molecular Genetics. 2006;15(Spec No 1):R95–R101.</Citation><ArticleIdList><ArticleId IdType="pubmed">16651376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy J.W., Caldas C., Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Research. 2015;75(15):2963–2968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539570</ArticleId><ArticleId IdType="pubmed">26180079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan Y., et al. Nutraceuticals: Unlocking newer paradigms in the mitigation of inflammatory lung diseases. Critical Reviews in Food Science and Nutrition. 2023;63(19):3302–3332.</Citation><ArticleIdList><ArticleId IdType="pubmed">34613853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H.W., et al. CRISPR–Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18. Gene Therapy. 2015;22(10):822–829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4600011</ArticleId><ArticleId IdType="pubmed">26043872</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa B.R.S., et al. Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity. Scientific Reports. 2018;8(1):4097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840339</ArticleId><ArticleId IdType="pubmed">29511269</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal A.S., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480–1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388482</ArticleId><ArticleId IdType="pubmed">25394791</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutting G.R., et al. Analysis of four diverse population groups indicates that a subset of cystic fibrosis mutations occur in common among Caucasians. The American Journal of Human Genetics. 1992;50(6):1185–1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682572</ArticleId><ArticleId IdType="pubmed">1376017</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneshdoust D., et al. Unlocking translational potential: Conditionally reprogrammed cells in advancing breast cancer research. Cells. 2023;12(19):2388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10572051</ArticleId><ArticleId IdType="pubmed">37830602</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneshdoust D., et al. Conditional reprogramming modeling of bladder cancer for clinical translation. Cells. 2023;12(13):1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10341071</ArticleId><ArticleId IdType="pubmed">37443748</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich D., et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. International Journal of Oncology. 2012;40(3):825–832.</Citation><ArticleIdList><ArticleId IdType="pubmed">22108652</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., et al. Preclinical application of conditional reprogramming culture system for laryngeal and hypopharyngeal carcinoma. Frontiers in Cell and Developmental Biology. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585768</ArticleId><ArticleId IdType="pubmed">34778255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenini G., et al. Genome editing of human primary keratinocytes by CRISPR/Cas9 reveals an essential role of the NLRP1 inflammasome in UVB sensing. Journal of Investigative Dermatology. 2018;138(12):2644–2652.</Citation><ArticleIdList><ArticleId IdType="pubmed">30096351</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlay J., et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941–1953.</Citation><ArticleIdList><ArticleId IdType="pubmed">30350310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao B., et al. Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget. 2017;8(7):11114–11126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5355251</ArticleId><ArticleId IdType="pubmed">28052041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentzsch M., et al. Pharmacological rescue of conditionally reprogrammed cystic fibrosis bronchial epithelial cells. American Journal of Respiratory Cell and Molecular Biology. 2017;56(5):568–574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5449492</ArticleId><ArticleId IdType="pubmed">27983869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gern J.E. Viral respiratory infection and the link to asthma. The Pediatric Infectious Disease Journal. 2008;27(10 Suppl):S97–S103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913380</ArticleId><ArticleId IdType="pubmed">18820588</ArticleId></ArticleIdList></Reference><Reference><Citation>Giard D.J., et al. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. Journal of the National Cancer Institute. 1973;51(5):1417–1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">4357758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillet J.P., Varma S., Gottesman M.M. The clinical relevance of cancer cell lines. Journal of the National Cancer Institute. 2013;105(7):452–458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691946</ArticleId><ArticleId IdType="pubmed">23434901</ArticleId></ArticleIdList></Reference><Reference><Citation>Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–1222. 10258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567026</ArticleId><ArticleId IdType="pubmed">33069326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowers K.H., et al. Optimized isolation and expansion of human airway epithelial basal cells from endobronchial biopsy samples. Journal of Tissue Engineering and Regenerative Medicine. 2018;12(1):e313–e317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811901</ArticleId><ArticleId IdType="pubmed">28488809</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S.B. Respiratory viral infections in adults. Current Opinion in Pulmonary Medicine. 2002;8(3):201–208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11981309</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708–1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilbault C., et al. Cystic fibrosis mouse models. American Journal of Respiratory Cell and Molecular Biology. 2007;36(1):1–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16888286</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad R.I., et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: Role, controversy, and future directions. Annals of Oncology. 2018;29(5):1130–1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961254</ArticleId><ArticleId IdType="pubmed">29635316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton N.J., et al. Using a three-dimensional collagen matrix to deliver respiratory progenitor cells to decellularized trachea in vivo. Tissue Engineering Part C Methods. 2019;25(2):93–102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389769</ArticleId><ArticleId IdType="pubmed">30648458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill S.J., D'Andrea A.D. Predictive potential of head and neck squamous cell carcinoma organoids. Cancer Discovery. 2019;9(7):828–830.</Citation><ArticleIdList><ArticleId IdType="pubmed">31262743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui K.P.Y., et al. Tropism, replication competence, and innate immune responses of influenza virus: An analysis of human airway organoids and ex-vivo bronchus cultures. Lancet Respiratory Medicine. 2018;6(11):846–854.</Citation><ArticleIdList><ArticleId IdType="pubmed">30001996</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo K.G., D'Arcangelo E., Tsao M.S. Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Translational Lung Cancer Research. 2020;9(5):2214–2232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7653147</ArticleId><ArticleId IdType="pubmed">33209645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynds R.E., et al. Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors. International Journal of Cancer. 2018;143(1):160–166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5969061</ArticleId><ArticleId IdType="pubmed">29569246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilse P., et al. SHOX2 DNA methylation is a tumour marker in pleural effusions. Cancer Genomics &amp;amp; Proteomics. 2013;10(5):217–223.</Citation><ArticleIdList><ArticleId IdType="pubmed">24136974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilse P., et al. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis. Cancer Genomics &amp;amp; Proteomics. 2014;11(5):251–258.</Citation><ArticleIdList><ArticleId IdType="pubmed">25331797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito R., et al. Recent advances in allergy research using humanized mice. International Journal of Molecular Sciences. 2019;20(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600417</ArticleId><ArticleId IdType="pubmed">31167385</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal-Hanjani M., et al. Tracking the evolution of non-small-cell lung cancer. New England Journal of Medicine. 2017;376(22):2109–2121.</Citation><ArticleIdList><ArticleId IdType="pubmed">28445112</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung M., et al. Novel paired normal prostate and prostate cancer model cell systems derived from African American patients. Cancer Research Communications. 2022;2(12):1617–1625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10035501</ArticleId><ArticleId IdType="pubmed">36970725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang L., et al. Trends of global and regional aetiologies, risk factors and mortality of lower respiratory infections from 1990 to 2019: An analysis for the Global Burden of Disease Study 2019. Respirology. 2023;28(2):166–175.</Citation><ArticleIdList><ArticleId IdType="pubmed">36210345</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRanger R., et al. Reconstituting mouse lungs with conditionally reprogrammed human bronchial epithelial cells. Tissue Engineering Part A. 2018;24(7–8):559–568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5905853</ArticleId><ArticleId IdType="pubmed">28726588</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiter A., Veluswamy R.R., Wisnivesky J.P. The global burden of lung cancer: Current status and future trends. Nature Reviews Clinical Oncology. 2023;20(9):624–639.</Citation><ArticleIdList><ArticleId IdType="pubmed">37479810</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., et al. Establishment of a diverse head and neck squamous cancer cell bank using conditional reprogramming culture methods. Journal of Medical Virology. 2023;95(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10168123</ArticleId><ArticleId IdType="pubmed">36477880</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol. 2012;180(2):599–607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3349876</ArticleId><ArticleId IdType="pubmed">22189618</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., et al. Conditionally reprogrammed cells (CRCs): A new model for cancer research and personalized medicine. Cancer Research. 2014;74(19_Supplement):2972. 2972.</Citation></Reference><Reference><Citation>Liu X., et al. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nature Protocols. 2017;12(2):439–451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195120</ArticleId><ArticleId IdType="pubmed">28125105</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., et al. Conditional reprogramming: Modeling urological cancer and translation to clinics. Clinical and Translational Medicine. 2020;10(2):e95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403683</ArticleId><ArticleId IdType="pubmed">32508060</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Wu Y., Rong L. Conditionally reprogrammed human normal airway epithelial cells at ALI: A physiological model for emerging viruses. Virologica Sinica. 2020;35(3):280–289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298165</ArticleId><ArticleId IdType="pubmed">32557270</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Cicero S., et al. L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: In vitro guided personalized therapy of non-F508del patients. Respiratory Research. 2023;24(1):217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10483775</ArticleId><ArticleId IdType="pubmed">37674160</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinovich K.M., et al. Conditionally reprogrammed primary airway epithelial cells maintain morphology, lineage and disease specific functional characteristics. Scientific Reports. 2017;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740081</ArticleId><ArticleId IdType="pubmed">29269735</ArticleId></ArticleIdList></Reference><Reference><Citation>McGranahan N., Swanton C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell. 2017;168(4):613–628.</Citation><ArticleIdList><ArticleId IdType="pubmed">28187284</ArticleId></ArticleIdList></Reference><Reference><Citation>Meganck R.M., et al. SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia. Cell Reports. 2024;43(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11165423</ArticleId><ArticleId IdType="pubmed">38607917</ArticleId></ArticleIdList></Reference><Reference><Citation>Meraz I.M., et al. An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunology Research. 2019;7(8):1267–1279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213862</ArticleId><ArticleId IdType="pubmed">31186248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal A.M., et al. Fidelity of a PDX-CR model for bladder cancer. Biochemical and Biophysical Research Communications. 2019;517(1):49–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777560</ArticleId><ArticleId IdType="pubmed">31303270</ArticleId></ArticleIdList></Reference><Reference><Citation>Msemburi W., et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613(7942):130–137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812776</ArticleId><ArticleId IdType="pubmed">36517599</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada S., Vaeteewoottacharn K., Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells. 2019;8(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6721637</ArticleId><ArticleId IdType="pubmed">31412684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ow T.J., et al. Characterization of a diverse set of conditionally reprogrammed head and neck cancer cell cultures. The Laryngoscope. 2024;134(6):2748–2756. doi: 10.1002/lary.31236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.31236</ArticleId><ArticleId IdType="pubmed">38288866</ArticleId></ArticleIdList></Reference><Reference><Citation>Palechor-Ceron N., et al. Radiation induces diffusible feeder cell factor (s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells. The American Journal of Pathology. 2013;183(6):1862–1870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745544</ArticleId><ArticleId IdType="pubmed">24096078</ArticleId></ArticleIdList></Reference><Reference><Citation>Palechor-Ceron N., et al. Conditional reprogramming for patient-derived cancer models and next-generation living biobanks. Cells. 2019;8(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6912808</ArticleId><ArticleId IdType="pubmed">31717887</ArticleId></ArticleIdList></Reference><Reference><Citation>Parekh K.R., et al. Stem cells and lung regeneration. American Journal of Physiology - Cell Physiology. 2020;319(4):C675–C693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654650</ArticleId><ArticleId IdType="pubmed">32783658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister D.G., et al. Head and neck cancers. Journal of the National Comprehensive Cancer Network. 2011;9(6):596–650.</Citation><ArticleIdList><ArticleId IdType="pubmed">21636536</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrowska Z., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discovery. 2015;5(7):713–722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497836</ArticleId><ArticleId IdType="pubmed">25934077</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasetyanti P.R., Medema J.P. Intra-tumor heterogeneity from a cancer stem cell perspective. Molecular Cancer. 2017;16(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5314464</ArticleId><ArticleId IdType="pubmed">28209166</ArticleId></ArticleIdList></Reference><Reference><Citation>Rani A.Q., et al. Conditional cell reprogramming and air–liquid interface modeling life cycle of oncogenic viruses (HPV and EBV) in epithelial cells and virus-associated human carcinomas. Viruses. 2023;15(6):1388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10302659</ArticleId><ArticleId IdType="pubmed">37376685</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts N., et al. Comparison of paired human nasal and bronchial airway epithelial cell responses to rhinovirus infection and IL-13 treatment. Clinical and Translational Medicine. 2018;7(1):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5931947</ArticleId><ArticleId IdType="pubmed">29721720</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosfjord E., et al. Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochemical Pharmacology. 2014;91(2):135–143.</Citation><ArticleIdList><ArticleId IdType="pubmed">24950467</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe R.G., Daley G.Q. Induced pluripotent stem cells in disease modelling and drug discovery. Nature Reviews Genetics. 2019;20(7):377–388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584039</ArticleId><ArticleId IdType="pubmed">30737492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rybinski B., Yun K. Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget. 2016;7(44):72322–72342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5342165</ArticleId><ArticleId IdType="pubmed">27608848</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed K., et al. Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer. European Urology. 2017;71(3):319–327.</Citation><ArticleIdList><ArticleId IdType="pubmed">27160946</ArticleId></ArticleIdList></Reference><Reference><Citation>Saffari P.S., et al. Most canine ameloblastomas harbor HRAS mutations, providing a novel large-animal model of RAS-driven cancer. Oncogenesis. 2019;8(2):11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6370874</ArticleId><ArticleId IdType="pubmed">30741938</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H., et al. Serially passaged, conditionally reprogrammed nasal epithelial cells as a model to study epithelial functions and SARS-CoV-2 infection. American Journal of Physiology - Cell Physiology. 2022;322(4):C591–c604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977148</ArticleId><ArticleId IdType="pubmed">35196166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., et al. A humanized mouse model of chronic COVID-19. Nature Biotechnology. 2022;40(6):906–920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9203605</ArticleId><ArticleId IdType="pubmed">34921308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette G., et al. Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells. International Journal of Cancer. 2018;143(1):88–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29341112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette G., et al. Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells. International Journal of Cancer. 2018;143(1):88–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29341112</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyoum S., et al. Cost burden among the CF population in the United States: A focus on debt, food insecurity, housing and health services. Journal of Cystic Fibrosis. 2023;22(3):471–477.</Citation><ArticleIdList><ArticleId IdType="pubmed">36710098</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltani-Zangbar M.S., et al. SARS-CoV2 infection induce miR-155 expression and skewed Th17/treg balance by changing SOCS1 level: A clinical study. Cytokine. 2023;169</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10247889</ArticleId><ArticleId IdType="pubmed">37307689</ArticleId></ArticleIdList></Reference><Reference><Citation>Stover E.H., et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. The Prostate. 2022;82(5):584–597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8887817</ArticleId><ArticleId IdType="pubmed">35084050</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Zhang Z. Patient-derived xenograft platform of OSCC: A renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization. Frontiers of Medicine. 2016;10(1):104–110.</Citation><ArticleIdList><ArticleId IdType="pubmed">26926009</ArticleId></ArticleIdList></Reference><Reference><Citation>Suprynowicz F.A., et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proceedings of the National Academy of Sciences of the U S A. 2012;109(49):20035–20040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523865</ArticleId><ArticleId IdType="pubmed">23169653</ArticleId></ArticleIdList></Reference><Reference><Citation>Talwelkar S.S., et al. Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. Cell Rep Med. 2021;2(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385325</ArticleId><ArticleId IdType="pubmed">34467250</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., et al. Pristimerin exacerbates cellular injury in conditionally reprogrammed patient-derived lung adenocarcinoma cells by aggravating mitochondrial impairment and endoplasmic reticulum stress through EphB4/CDC42/N-WASP signaling. Oxidative Medicine and Cellular Longevity. 2020;2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7369684</ArticleId><ArticleId IdType="pubmed">32733636</ArticleId></ArticleIdList></Reference><Reference><Citation>Tata P.R., et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature. 2013;503(7475):218–223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035230</ArticleId><ArticleId IdType="pubmed">24196716</ArticleId></ArticleIdList></Reference><Reference><Citation>Timofeeva O.A., et al. Conditionally reprogrammed normal and primary tumor prostate epithelial cells: A novel patient-derived cell model for studies of human prostate cancer. Oncotarget. 2017;8(14)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5410259</ArticleId><ArticleId IdType="pubmed">28009986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran B.M., et al. Air-liquid-interface differentiated human nose epithelium: A robust primary tissue culture model of SARS-CoV-2 infection. International Journal of Molecular Sciences. 2022;23(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776210</ArticleId><ArticleId IdType="pubmed">35055020</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerati P.C., et al. Conditionally reprogrammed asthmatic bronchial epithelial cells express lower FOXJ1 at terminal differentiation and lower IFNs following RV-A1 infection. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2022;323(4):L495–L502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9602788</ArticleId><ArticleId IdType="pubmed">36041223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagers A.J. The stem cell niche in regenerative medicine. Cell Stem Cell. 2012;10(4):362–369.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482502</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh N.C., et al. Humanized mouse models of clinical disease. Annual Review of Pathology: Mechanisms of Disease. 2017;12:187–215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5280554</ArticleId><ArticleId IdType="pubmed">27959627</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. 2024. https://data.who.int/dashboards/covid19/cases?n=c Available from:</Citation></Reference><Reference><Citation>Wu X., et al. Conditional reprogramming: Next generation cell culture. Acta Pharmaceutica Sinica B. 2020;10(8):1360–1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488362</ArticleId><ArticleId IdType="pubmed">32963937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M., et al. Personalized drug testing in a patient with non-small-cell lung cancer using cultured cancer cells from pleural effusion. Journal of International Medical Research. 2020;48(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7509736</ArticleId><ArticleId IdType="pubmed">32954884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G.D., et al. Monitoring of lung malignant epithelial cells by gene methylation analysis in the conditionally reprogrammed cell cultures. Neoplasma. 2020;67(3):692–699.</Citation><ArticleIdList><ArticleId IdType="pubmed">32202907</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F., et al. Non-malignant epithelial cells preferentially proliferate from nasopharyngeal carcinoma biopsy cultured under conditionally reprogrammed conditions. Scientific Reports. 2017;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727117</ArticleId><ArticleId IdType="pubmed">29234119</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F., et al. Non-malignant epithelial cells preferentially proliferate from nasopharyngeal carcinoma biopsy cultured under conditionally reprogrammed conditions. Scientific Reports. 2017;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727117</ArticleId><ArticleId IdType="pubmed">29234119</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Seminars in Cancer Biology. 2002;12(6):421–429.</Citation><ArticleIdList><ArticleId IdType="pubmed">12450728</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H., et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. New England Journal of Medicine. 2012;367(13):1220–1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030597</ArticleId><ArticleId IdType="pubmed">23013073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao R., et al. Conditional cell reprogramming in modeling digestive system diseases. Frontiers in Cell and Developmental Biology. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8211013</ArticleId><ArticleId IdType="pubmed">34150763</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong M., Fu L. Culture and application of conditionally reprogrammed primary tumor cells. Gastroenterology Report. 2020;8(3):224–233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333928</ArticleId><ArticleId IdType="pubmed">32665854</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>